Radiotherapy de-escalation strategies show reduced toxicity but modest clinical benefits in head and neck cancer cohorts.

This narrative review evaluates radiotherapy de-escalation strategies, including elective neck dose- and volume de-escalation, personalized approaches, risk-stratified methods, response-guided radiotherapy, adaptive radiotherapy, and proton therapy. The analysis covers unselected patient cohorts and intermediate-risk patients with head and neck squamous cell carcinoma or HPV-related oropharyngeal cancer. Standard radiotherapy served as the comparator for assessing oncologic and toxicity outcomes.

Regarding oncologic outcomes, isolated regional recurrence rates were reported as very low across the reviewed strategies. However, clinical benefits in these unselected cohorts were described as modest. Conversely, outcomes for cure and survival were noted as inferior in some contexts. The review did not report specific absolute numbers, p-values, or confidence intervals for these findings.

In terms of safety and tolerability, acute toxicity was reduced with de-escalation strategies, and dosimetric sparing was substantial. Treatment-related side effects were identified as a primary outcome, though specific adverse event rates or discontinuation data were not reported. The review highlighted that broad implementation remains limited by cost and access issues.

Key limitations include the modest clinical benefits observed in unselected patient cohorts and the lack of specific statistical data. The practice relevance lies in strategies aimed at reducing side effects without compromising oncologic outcomes, though clinicians must interpret these findings cautiously given the narrative nature of the evidence and the absence of randomized trial data.